Why Is Channel Therapeutics Stock Surging On Friday?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2025
0mins
Should l Buy ?
Source: Benzinga
Reverse Stock Split Announcement: Channel Therapeutics Corporation announced a 10-for-1 reverse stock split to increase its share price and meet NYSE American listing requirements ahead of a merger with LNHC, Inc.
Shareholder Impact: The reverse split will reduce outstanding shares from approximately 6.5 million to about 648,500, but ownership percentages will remain unchanged, and trading under the new name Pelthos Therapeutics Inc. will begin on July 2, 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
